We read with interest the article by Feng et al. [1] entitled ‘‘Comparison of endoscopic papillary large balloon dilation and endoscopic sphincterotomy for retrieval of choledocholithiasis: a meta-analysis of randomized controlled trials’’, which discussed the efficacy and safety of endoscopic large balloon dilation (EPLBD) and endoscopic sphincterotomy (EST) for the treatment of choledocholithiasis. The authors tried to do a systematic review and metaanalysis of the ‘‘randomized controlled trials (RCT)’’ from several databases, two of which are actually retrospective studies [2, 3]. EST has been a standard endoscopic treatment for the removal of common bile duct (CBD) stones, but it is inclined to cause pancreatitis, bleeding, and perforation. Recently, EPLBD has been advocated as an alternative to EST for the management of CBD stones, though it may have a higher risk of post-ERCP pancreatitis (PEP). It remains controversial whether EPLBD is comparable to EST with regard to the feasibility and safety for the management of CBD stones, especially large or difficult stones. In this review, the authors demonstrated that EPLBD was equivalent to EST for the removal of large stones. However, among the seven included studies, only one compared EPLBD and EST, and the other six compared endoscopic balloon dilation following EST (ESLBD) and EST, which is another serious issue. The combination of these two kinds of studies is not recommended by the Cochrane handbook, because it will cause unknown biases by combining ‘‘apples’’ with ‘‘oranges’’ [4]. Furthermore, ESLBD is a different endoscopic treatment for choledocholithiasis, which can combine the merits of EPLBD and EST. Therefore, it is inappropriate to draw the conclusion by summarizing the results from studies comparing ESLBD versus EST and EPLBD versus EST. Endoscopic mechanical lithotripsy (EML) will be needed as a remedy when stones fail to be removed, a problem which has been found to be reduced in the EPLBD group. However, the enrolled study by Stefanidis [5] applied EML to all the patients of the EST group but none of the EPLBD group, which will probably increase the overall usage of EML in the EST group. Post-ERCP hemorrhage is another serious complication after sphincterotomy or balloon dilation, the risk of which was found to be lower in the EPLBD group. However, nine patients with uncorrected coagulopathy were enrolled in the study by Garcia-Cano [3] and thus it should be excluded from Feng’s study, or sensitivity analysis should be done to explore whether it was biased and able to be included in the meta-analysis.
Read full abstract